18 and older, any sex, with AIDS-Related Primary Effusion Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Differential Gene Expression Profile by RNA-Seq or GeneChip AssaysPrimary· baseline
The resultant data will be a subset of the whole analysis population due to RNAseq data availability. It will be assessed for quality, normalized, and then analyzed for differential gene expression. The Nanostring software nSolver will be used to do quality control, background subtraction, normalization, and analysis of the differential expression for RNA-sequencing data. Lastly, bioinformatic analysis approaches will be used to help make sense of possible biological links between the genes found to be differentially expressed between the sample groups that may be of prognostic significance. 1
Group
Value
95% CI
Survival Less Than 2 Years With Available RNAseq Data
4
Survival More Than or Equal to 2 Years With Available RNAseq Data
15
Response RatesPrimary· Up to 1 year
The number of participants for this outcome measure is 25 participants with baseline characteristics and response evaluation. Since this was a retrospective study, response criteria were not defined. Response determinations as recorded in the medical record by the treating physician were abstracted on each participant for data analysis. Response rates will be reported with 95% confidence intervals (binomial distribution). Descriptive statistics will be used to summarize baseline clinical, histological, and viral characteristics.
Complete response
Group
Value
95% CI
Survival Less Than 2 Years
1
Survival More Than or Equal to 2 Years
13
Partial response
Group
Value
95% CI
Survival Less Than 2 Years
2
Survival More Than or Equal to 2 Years
2
Stable disease
Group
Value
95% CI
Survival Less Than 2 Years
2
Survival More Than or Equal to 2 Years
2
Progression
Group
Value
95% CI
Survival Less Than 2 Years
3
Survival More Than or Equal to 2 Years
3
Survival Status at 2 YearsPrimary· At 2 years post diagnosis
Survival duration will be determined using the elapsed time between the date of PEL diagnosis and the last follow-up date or the date of death.
Hispanic
Group
Value
95% CI
Survival Less Than 2 Years
2
Survival More Than or Equal to 2 Years
5
Non-Hispanic
Group
Value
95% CI
Survival Less Than 2 Years
6
Survival More Than or Equal to 2 Years
12
White
Group
Value
95% CI
Survival Less Than 2 Years
5
Survival More Than or Equal to 2 Years
9
Non-White
Group
Value
95% CI
Survival Less Than 2 Years
3
Survival More Than or Equal to 2 Years
8
EPOCH treatment
Group
Value
95% CI
Survival Less Than 2 Years
4
Survival More Than or Equal to 2 Years
13
Non-EPOCH treatment
Group
Value
95% CI
Survival Less Than 2 Years
4
Survival More Than or Equal to 2 Years
4
Stage I-III
Group
Value
95% CI
Survival Less Than 2 Years
2
Survival More Than or Equal to 2 Years
6
Stage IV
Group
Value
95% CI
Survival Less Than 2 Years
6
Survival More Than or Equal to 2 Years
11
Sponsor's own description
This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
· withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men
· withdrawn
NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance
· Phase 1, PHASE2
· recruiting
NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
· Phase 1
· active not recruiting
NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
· Phase 1
· active not recruiting
Other recruiting trials for AIDS-Related Primary Effusion Lymphoma
Currently open trials in the same condition.
NCT02337985 — Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
· Phase 1
· active not recruiting
Other AIDS Malignancy Consortium trials
Trials by the same sponsor.
NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
· withdrawn
NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men
· withdrawn
NCT05077527 — Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
· Phase 1
· recruiting
NCT04305691 — Trial of Ixazomib for Kaposi Sarcoma
· Phase 2
· recruiting
NCT05510908 — Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AIDS Malignancy Consortium
Last refreshed: 11 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02823327.